Alnylam Pharmaceuticals (ALNY) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
United Therapeutics (UTHR) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 18.7% versus a loss of 50.2%. Over five years, UTHR leads with a +184.8% price change compared with +7.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($30.94 billion vs $23.62 billion), about 1.3 times the size.
On valuation, United Therapeutics trades at a lower forward P/E (16.3x vs 18.6x for Alnylam Pharmaceuticals). United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | UTHR |
|---|---|---|
| Share price | $231.21 | $550.68 |
| Market cap | $30.94B | $23.62B |
| 1-day change | +2.98% | +3.36% |
| YTD return | -43.54% | +9.34% |
| 1-year return | -50.18% | +18.68% |
| 5-year return | +7.66% | +184.80% |
| P/E ratio (TTM) | 38.99 | 19.72 |
| Forward P/E | 18.61 | 16.30 |
| EPS (TTM) | $5.93 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $3.18B |
| Revenue growth (YoY) | +65.19% | +10.61% |
| Net income (latest FY) | $313.75M | $1.33B |
| Gross margin | 81.77% | 87.92% |
| Operating margin | 13.51% | 46.89% |
| Net margin | 8.45% | 41.94% |
| 52-week high | $495.55 | $609.35 |
| 52-week low | $197.81 | $409.07 |
| Distance from 52-week high | -53.34% | -9.63% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +60.51% | +17.97% |
| Average volume | 1.78M | 672.80K |
| Shares outstanding | 133.81M | 42.89M |
| Employees | 2,500 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UTHR has outperformed ALNY by 68.9 percentage points over the past year.
- Alnylam Pharmaceuticals trades at a higher earnings multiple (39.0x vs 19.7x trailing P/E).
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus 8.4 cents for Alnylam Pharmaceuticals.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +10.61%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
ALNY vs UTHR FAQ
Which is bigger, Alnylam Pharmaceuticals or United Therapeutics?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $30.94B compared with $23.62B for United Therapeutics (UTHR).
Which stock has performed better over the past year, ALNY or UTHR?
UTHR returned +18.68% over the past 12 months, compared with -50.18% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or UTHR?
UTHR has the lower trailing P/E at 19.7, versus 39.0 for ALNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alnylam Pharmaceuticals and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.